🎀 GYN Oncology — 2026-W38

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

Phase 3 randomized, double-blind trial in previously untreated BRCA-non-mutated advanced epithelial ovarian cancer, published in Lancet Oncology. Tests adding pembrolizumab and/or olaparib maintenance to first-line chemotherapy, directly informing first-line treatment strategy for this large patient subgroup.

Long-term (5-year) exploratory follow-up analysis of the phase 3 KEYNOTE-826 trial in previously untreated persistent/recurrent/metastatic cervical cancer, published in JAMA Oncology. Confirms durable survival benefit of adding pembrolizumab to platinum-based chemotherapy (± bevacizumab), reinforcing this as standard first-line therapy.

Narrative review in Cancer (Q1) summarizing the evolving role of checkpoint inhibitors, combination strategies, and biomarkers in advanced ovarian cancer treatment. Clarifies where immunotherapy currently adds benefit (platinum-resistant, PD-L1-positive disease) versus where evidence remains limited, informing treatment sequencing discussions.

Translational transcriptomic analysis from a phase 1 trial of intraperitoneal monocytes plus interferons in platinum-resistant recurrent ovarian cancer, published in Journal for ImmunoTherapy of Cancer. Identifies immune signatures and chemokines associated with long-term response, informing which patients may benefit from this experimental cellular immunotherapy.

Translational/correlative study in Gynecologic Oncology examining how TP53 mutation status alters type I interferon pathway expression and signaling in endometrial cancer tissue and TCGA data. Findings are mechanistic and prognostic in nature, without demonstrating a direct link to response to a specific therapy.